From structural design to delivery: mRNA therapeutics for cancer immunotherapy
Exploration · 2024-04 · 4 (2)
DOI: 10.1002/exp.20210146 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Exploration, online erschienen am 17.11.2023. Verfasst von Feng Zhou und 17 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai China. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 308 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
mRNA therapeutics have emerged as powerful tools for cancer immunotherapy in accordance with their superiority in expressing all sequence‐known proteins in vivo. In particular, with a small dosage of delivered mRNA, antigen‐presenting cells (APCs) can synthesize mutant neo‐antigens and multi‐antigens and present epitopes to T lymphocytes to elicit antitumor effects. In addition, expressing receptors like chimeric antigen receptor (CAR), T‐cell receptor (TCR), CD134, and immune‐modulating factors including cytokines, interferons, and antibodies in specific cells can enhance immunological response against tumors. With the maturation of in vitro transcription (IVT) technology, large‐scale and pure mRNA encoding specific proteins can be synthesized quickly. However, the clinical translation of mRNA‐based anticancer strategies is restricted by delivering mRNA into target organs or cells and the inadequate endosomal escape efficiency of mRNA. Recently, there have been some advances in mRNA‐based cancer immunotherapy, which can be roughly classified as modifications of the mRNA structure and the development of delivery systems, especially the lipid nanoparticle platforms. In this review, the latest strategies for overcoming the limitations of mRNA‐based cancer immunotherapies and the recent advances in delivering mRNA into specific organs and cells are summarized. Challenges and opportunities for clinical applications of mRNA‐based cancer immunotherapy are also discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai China.
- University of Chinese Academy of Sciences Beijing China.
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou China.
- Department of Applied Physics University of Eastern Finland Kuopio Finland.
- Department of Pharmaceutical Sciences University of Vienna Vienna Austria.
- Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery Ministry of Education, Fudan University Shanghai China.
ORCID-Profile: Xiaolong Liu, Ulrich Lächelt, Wei Tao, Haijun Yu
Förderung
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Zhou, F., Huang, L., Li, S., Yang, W., Chen, F., Cai, Z., Liu, X., Xu, W., Lehto, V. P., Lächelt, U., Huang, R., Shi, Y., Lammers, T., Tao, W., Xu, Z. P., Wagner, E., Xu, Z., & Yu, H. (2024). From structural design to delivery: mRNA therapeutics for cancer immunotherapy. Exploration, 4(2). https://doi.org/10.1002/exp.20210146
Vancouver
Zhou F, Huang L, Li S, Yang W, Chen F, Cai Z, et al. From structural design to delivery: mRNA therapeutics for cancer immunotherapy. Exploration. 2024;4(2). doi:10.1002/exp.20210146
BibTeX
@article{Zhou2024,
author = {Zhou, Feng and Huang, Lujia and Li, Shiqin and Yang, Wenfang and Chen, Fangmin and Cai, Zhixiong and Liu, Xiaolong and Xu, Wujun and Lehto, Vesa-Pekka and Lächelt, Ulrich and Huang, Rongqin and Shi, Yang and Lammers, Twan and Tao, Wei and Xu, Zhi Ping and Wagner, Ernst and Xu, Zhiai and Yu, Haijun},
title = {From structural design to delivery: mRNA therapeutics for cancer immunotherapy},
journal = {Exploration},
year = {2024},
volume = {4},
number = {2},
doi = {10.1002/exp.20210146}
}
EUVIMED